查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球生技药品CDMO 市场：2023-2033
市场调查报告书
商品编码
1379213

全球生技药品CDMO 市场：2023-2033

Global Biologics CDMO Market - A Global and Regional Analysis, 2023-2033
出版日期: | 出版商: BIS Research | 英文 165 Pages | 商品交期: 1-5个工作天内

价格
简介目录

全球生技药品CDMO 市场预计将在创新和需求浪潮中快速成长。

全球生技药品CDMO 市场透过为生技药品的开发、製造和测试提供专业服务，在製药和生物技术产业中发挥重要作用。生技药品是源自活生物体的复杂分子，例如蛋白质、抗体和核酸，在治疗多种疾病（包括癌症、自体免疫疾病和感染疾病）方面变得越来越重要。

本报告调查了全球生技药品CDMO 市场，并提供了市场概况，分析了市场成长的各种影响因素、法律制度、市场规模趋势和预测，并对各个细分市场、地区和主要国家进行了详细分析、竞争形势、主要企业分析等

市场区隔：

细分 1：按细胞类型

  • 哺乳动物的
  • 非哺乳动物

细分 2：依产品类型

  • 生技药品
    • 单株抗体
    • 重组蛋白
    • 反义/分子药物
    • 疫苗
    • 其他的
  • 生物相似药

细分 3：按地区

  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

目录

第1章市场：产业展望

  • 趋势：当前和未来的影响评估
    • 新的基因疗法和细胞疗法
    • 免洗生物加工设备
    • 个人化医疗的趋势
  • 供应链概览
    • 价值链分析
    • 市场地图
    • 製造成本预测：CDMO/gm
  • 专利分析
  • 法规状况
  • 製造能力
  • 外包给 CDMO 时考虑的因素
  • 世界重大事件的影响分析：COVID-19、俄罗斯/乌克兰、中东危机
  • 市场动态概览
    • 市场驱动因素
    • 市场抑制因素
    • 市场机会

第2章应用

  • 使用分类
  • 应用概述
  • 全球生技药品CDMO 市场（按细胞类型）
    • 哺乳动物的
    • 非哺乳动物

第3章产品

  • 产品分类
  • 产品概要
  • 全球生技药品CDMO 市场（依产品类型）
    • 生技药品
    • 生物相似药

第4章区域

  • 区域概况
  • 促进因素/抑制因素
  • 北美洲
    • 主要参与企业
    • 业务促进因素
    • 业务挑战
    • 目的
    • 产品
    • 北美洲（按国家/地区）
  • 欧洲
    • 主要参与企业
    • 业务促进因素
    • 业务挑战
    • 目的
    • 产品
    • 欧洲（按国家/地区）
  • 亚太地区
    • 主要参与企业
    • 业务促进因素
    • 业务挑战
    • 目的
    • 产品
    • 亚太地区（按国家/地区）
  • 拉丁美洲
    • 主要参与企业
    • 业务促进因素
    • 业务挑战
    • 目的
    • 产品
    • 拉丁美洲（按国家/地区）
  • 中东/非洲
    • 主要参与企业
    • 业务促进因素
    • 业务挑战
    • 目的
    • 产品
    • 中东/非洲（按国家）

第5章市场：竞争形势/公司简介

  • 竞争形势
  • 公司简介
    • Boehringer Ingelheim Group
    • Lonza Group
    • Samsung Biologics
    • NOVARTIS AG
    • Toyobo Co. Limited
    • Parexel International Corporation
    • Catalent Inc.
    • Binex Co. Limited
    • AGC Biologics
    • AbbVie Contract Manufacturing
简介目录
Product Code: BHL1501SA

“Global Biologics CDMO Market Set to Surge, Riding the Wave of Innovation and Demand.”

Biologics CDMO Industry Overview

Introduction to Biologics CDMO Market

The global biologics CDMO market plays a crucial role in the pharmaceutical and biotechnology industries, offering specialized services for the development, manufacturing, and testing of biologic drugs. Biologics are complex molecules derived from living organisms, such as proteins, antibodies, and nucleic acids, and they have become increasingly important in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases.

CDMOs in the biologics sector provide a range of services, including cell line development, process development, scale-up, manufacturing, quality control, and regulatory support. These organizations serve as strategic partners for pharmaceutical and biotech companies, allowing them to outsource certain aspects of the drug development and manufacturing process, thereby gaining efficiency, expertise, and flexibility.

Market Segmentation:

Segmentation 1: by Cell Type

  • Mammalian
  • Non-mammalian

Segmentation 2: by Product Type

  • Biologics
    • Monoclonal Antibodies
    • Recombinant Proteins
    • Antisense and Molecular Therapy
    • Vaccines
    • Other Biologics
  • Biosimilars

Segmentation 3: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • MEA

The report provides data for each of these regions, with in-depth country-level analyses, all covering the period from 2022 to 2033.

SegmentationHow can this report add value to an organization?

Product/Innovation Strategy: The global biologics CDMO market has been extensively segmented based on various categories, such as cell type and product type. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: The global biologics CDMO market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint venture.

Competitive Strategy: Key players in the global biologics CDMO market analyzed and profiled in the study involve established and emerging players. Moreover, a detailed competitive benchmarking of the players operating in the global biologics CDMO market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, product portfolio, and market penetration.

SegmentationSome of the prominent names established in this market are:

  • Boehringer Ingelheim Group
  • Lonza Group
  • Samsung Biologics
  • NOVARTIS AG
  • Toyobo Co. Limited
  • Parexel International Corporation
  • Catalent Inc.
  • Binex Co. Limited
  • AGC Biologics
  • AbbVie Contract Manufacturing

Table of Contents

1. Markets: Industry Outlook

  • 1.1. Trends: Current and Future Impact Assessment
    • 1.1.1. Emerging Gene and Cell Therapies
    • 1.1.2. Single-use Bioprocessing Equipment
    • 1.1.3. Trend Toward Personalized Medicine
  • 1.2. Supply Chain Overview
    • 1.2.1. Value chain Analysis
    • 1.2.2. Market Map
    • 1.2.3. Cost of Manufacturing in CDMO/gm Forecast
  • 1.3. Patent Analysis
    • 1.3.1. Awaited Technological Developments
    • 1.3.2. Patent Filing Trend by Country, by Year
    • 1.3.3. Patent Filing Trend by Country, by Country
  • 1.4. Regulatory Landscape
  • 1.5. Prodution Capacity
  • 1.6. Factors Considered While Outsourcing To CDMO
  • 1.7. Impact analysis for key global events- covid19, Russia/Ukraine or Middle East crisis
  • 1.8. Market Dynamics Overview
    • 1.8.1. Market Drivers
    • 1.8.2. Market Restraints
    • 1.8.3. Market Opportunities

2. Application

  • 2.1. Application Segmentation
  • 2.2. Application Summary
  • 2.3. Global Biologiv CDMO Market (by Cell Type)
    • 2.3.1. Mammalian
    • 2.3.2. Non-mammalian

3. Product

  • 3.1. Product Segmentation
  • 3.2. Product Summary
  • 3.3. Global Biologics CDMO Market (by Product Type)
    • 3.3.1. Biologics
      • 3.3.1.1. Monoclonal Antibodies
      • 3.3.1.2. Recombinant Proteins
      • 3.3.1.3. Antisense and Molecular Therapy
      • 3.3.1.4. Vaccines
      • 3.3.1.5. Other Biologics
    • 3.3.2. Biosimilars

4. Region

  • 4.1. Regional Summary
    • Table: Biologics CDMO Market, By Region, ($ Million), 2022-2033
  • 4.2. Drivers and Restraints
  • 4.3. North America
    • Key Market Participants in North America
    • Business Drivers
    • Business Challenges
    • 4.3.1. Application
      • Table: North America Biologics CDMO Market, By Cell Type ($ Million), 2022-2033
    • 4.3.2. Product
      • Table: North America Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
    • 4.3.3. North America (by Country)
      • 4.3.3.1. U.S.
        • Table: U.S. Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: U.S. Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.3.3.2. Canada
        • Table: U.S. Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: U.S. Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
  • 4.4. Europe
    • Key Market Participants in Europe
    • Business Drivers
    • Business Challenges
    • 4.4.1. Application
      • Table: Europe Biologics CDMO Market, By Cell Type ($ Million), 2022-2033
    • 4.4.2. Product
      • Table: Europe Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
    • 4.4.3. Europe (by Country)
      • 4.4.3.1. U.K.
        • Table: U.K.Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: U.K. Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.4.3.2. Germany
        • Table: Germany Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Germany Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.4.3.3. Italy
        • Table: Italy Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Italy Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.4.3.4. France
        • Table: France Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: France Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.4.3.5. Spain
        • Table: Spain Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Spain Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.4.3.6. Rest of Europe
        • Table: Rest of Europe Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Rest of Europe Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
  • 4.5. Asia Pacific
    • Key Market Participants in Asia Pacific
    • Business Drivers
    • Business Challenges
    • 4.5.1. Application
      • Table: Europe Biologics CDMO Market, By Cell Type ($ Million), 2022-2033
    • 4.5.2. Product
      • Table: Europe Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
    • 4.5.3. Asia Pacific (by Country)
      • 4.5.3.1. China
        • Table: China Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: China Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.5.3.2. Japan
        • Table: Japan Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Japan Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.5.3.3. India
        • Table: India Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: India Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.5.3.4. Australia
        • Table: Australia Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Australia Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.5.3.5. Rest of APAC
        • Table: Rest of APAC Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Rest of APAC Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
  • 4.6. Latin America
    • Key Market Participants in Latin America
    • Business Drivers
    • Business Challenges
    • 4.6.1. Application
      • Table: Latin America Biologics CDMO Market, By Cell Type ($ Million), 2022-2033
    • 4.6.2. Product
      • Table: Latin America Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
    • 4.6.3. Latin America (by Country)
      • 4.6.3.1. Brazil
        • Table: Brazil Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Brazil Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.6.3.2. Mexico
        • Table: Mexico Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Mexico Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.6.3.3. Rest of Latin America
        • Table: Rest of Latin America Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Rest of Latin America Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
  • 4.7. MEA
    • Key Market Participants in MEA
    • Business Drivers
    • Business Challenges
    • 4.7.1. Application
      • Table: MEA Biologics CDMO Market, By Cell Type ($ Million), 2022-2033
    • 4.7.2. Product
      • Table: MEA Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
    • 4.7.3. MEA (by Country)
      • 4.7.3.1. Saudi Arabia
        • Table: Saudi Arabia Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Saudi Arabia Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.7.3.2. U.A.E.
        • Table: U.A.E. Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: U.A.E. Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.7.3.3. Rest of MEA
        • Table: Rest of MEA Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Rest of MEA Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033

5. Markets - Competitive Landscape & Company Profiles

  • 5.1. Competitive Landscape
  • 5.2. Company Profile
    • 5.2.1. Boehringer Ingelheim Group
      • 5.2.1.1. Company Overview
        • 5.2.1.1.1. Role of Boehringer Ingelheim Group in Biologics CDMO Market
        • 5.2.1.1.2. Product Portfolio
      • 5.2.1.2. Business Strategies
      • 5.2.1.3. Corporate Strategies
      • 5.2.1.4. Analyst View
    • 5.2.2. Lonza Group
      • 5.2.2.1. Company Overview
        • 5.2.2.1.1. Role of Lonza Group in Biologics CDMO Market
        • 5.2.2.1.2. Product Portfolio
      • 5.2.2.2. Business Strategies
      • 5.2.2.3. Corporate Strategies
      • 5.2.2.4. Analyst View
    • 5.2.3. Samsung Biologics
      • 5.2.3.1. Company Overview
        • 5.2.3.1.1. Role of Samsung Biologics in Biologics CDMO Market
        • 5.2.3.1.2. Product Portfolio
      • 5.2.3.2. Business Strategies
      • 5.2.3.3. Corporate Strategies
      • 5.2.3.4. Analyst View
    • 5.2.4. NOVARTIS AG
      • 5.2.4.1. Company Overview
        • 5.2.4.1.1. Role of NOVARTIS AG in Biologics CDMO Market
        • 5.2.4.1.2. Product Portfolio
      • 5.2.4.2. Business Strategies
      • 5.2.4.3. Corporate Strategies
      • 5.2.4.4. Analyst View
    • 5.2.5. Toyobo Co. Limited
      • 5.2.5.1. Company Overview
        • 5.2.5.1.1. Role of Toyobo Co. Limited Group in Biologics CDMO Market
        • 5.2.5.1.2. Product Portfolio
      • 5.2.5.2. Business Strategies
      • 5.2.5.3. Corporate Strategies
      • 5.2.5.4. Analyst View
    • 5.2.6. Parexel International Corporation
      • 5.2.6.1. Company Overview
        • 5.2.6.1.1. Role of Parexel International Corporation in Biologics CDMO Market
        • 5.2.6.1.2. Product Portfolio
      • 5.2.6.2. Business Strategies
      • 5.2.6.3. Corporate Strategies
      • 5.2.6.4. Analyst View
    • 5.2.7. Catalent Inc.
      • 5.2.7.1. Company Overview
        • 5.2.7.1.1. Role of Catalent Inc. in Biologics CDMO Market
        • 5.2.7.1.2. Product Portfolio
      • 5.2.7.2. Business Strategies
      • 5.2.7.3. Corporate Strategies
      • 5.2.7.4. Analyst View
    • 5.2.8. Binex Co. Limited
      • 5.2.8.1. Company Overview
        • 5.2.8.1.1. Role of Binex Co. Limited in Biologics CDMO Market
        • 5.2.8.1.2. Product Portfolio
      • 5.2.8.2. Business Strategies
      • 5.2.8.3. Corporate Strategies
      • 5.2.8.4. Analyst View
    • 5.2.9. AGC Biologics
      • 5.2.9.1. Company Overview
        • 5.2.5.1.1. Role of AGC Biologics in Biologics CDMO Market
        • 5.2.5.1.2. Product Portfolio
      • 5.2.9.2. Business Strategies
      • 5.2.9.3. Corporate Strategies
      • 5.2.9.4. Analyst View
    • 5.2.10. AbbVie Contract Manufacturing
      • 5.2.10.1. Company Overview
        • 5.2.10.1.1. Role of AbbVie Contract Manufacturing in Biologics CDMO Market
        • 5.2.10.1.2. Product Portfolio
      • 5.2.10.2. Business Strategies
      • 5.2.10.3. Corporate Strategies
      • 5.2.10.4. Analyst View